Physician profile
David C Reesman
NPI 1609369164
$8,546.01
in general payments reported to CMS, 2019-2025
27 companies · $2,862 in 2025
The $2,862 reported for 2025 was more than what 98% of Occupational Health (Nurse Practitioner) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,025 · 2023: $2,000 · 2024: $2,659 · 2025: $2,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,521.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,518.84 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $739.53 | 2023-2025 | Ingrezza |
| Abiomed | $605.39 | 2023-2025 | Impella |
| Amgen INC. | $604.71 | 2022-2025 | Krystexxa |
| Abbott Laboratories | $393.67 | 2023-2024 | Freestyle Libre 3, Cardiomems, Mitraclip |
| Sanofi Pasteur INC. | $374.30 | 2023-2025 | |
| Boston Scientific Corporation | $364.73 | 2023-2025 | Watchman Flx, Watchman Access System |
| Actelion Pharmaceuticals US, INC. | $352.46 | 2023-2025 | Uptravi, Opsumit |
| Genzyme Corporation | $345.55 | 2023-2025 | |
| Novo Nordisk INC | $344.07 | 2022-2025 | Ozempic |
| Corcept Therapeutics | $342.67 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $327.46 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $314.24 | 2022-2025 | Airsupra |
| Insmed, INC. | $300.02 | 2024-2025 | Arikayce |
| Teva Pharmaceuticals USA, INC. | $229.29 | 2022-2023 | Austedo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $186.46 | 2023-2024 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $180.23 | 2023-2024 | |
| Cvrx, INC. | $137.79 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $127.62 | 2022 | |
| Axonics, INC. | $118.06 | 2024 | Axonics, Bulkamid |
| Argenx US, INC. | $115.75 | 2025 | Vyvgart |
| Alkermes, INC. | $114.75 | 2023 | Lybalvi |
| Paratek Pharmaceuticals, INC. | $113.72 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.18 | 2024 | Jardiance |
| Lucid Diagnostics INC. | $100.43 | 2023 | |
| Idorsia Pharmaceuticals US INC | $62.40 | 2023 | Quviviq |
| Medtronic, INC. | $30.69 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reesman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.